Brexogen, a leading biotechnology company specialising in exosome-based therapeutics, has announced a technology transfer and licensing agreement with BMI Korea for BxC-I17e, an innovative exosome-based injectable therapeutic.
This agreement marks the first major licensing deal for an exosome therapeutic in Korea, signifying a major milestone in the commercialization of exosome-based medicines.
While financial terms remain confidential, Brexogen will receive KRW 3 billion (approximately $2.3 million) as a non-refundable upfront payment.
BMI Korea, a pharmaceutical company with annual revenues exceeding KRW 100 billion ($77 million), specialises in prescription drugs, biologics, medical devices, and aesthetic products. The company operates large-scale contract manufacturing (CMO) facilities in Jeju and Osong, Chungbuk, with extensive expertise in regulatory approvals, production, and commercialization.
Under this partnership, BxC-I17e will be manufactured at BMI Korea's cutting-edge facilities, ensuring scalability for both clinical and commercial supply.
To date, globally, there is no approved exosome-based therapeutics for commercial use. This partnership is expected to drive innovation in exosome drug development and set new industry standards.
Founded in 2019, Brexogen's flagship programme, BRE-AD01 for atopic dermatitis, is currently in Phase 1 clinical trials in the U.S.
Brexogen has also successfully commercialised BREXTEM-S (for skin rejuvenation) and BREXTEM-H (for hair restoration), offering exosome-based solutions for clinical and hospital use. Looking ahead, Brexogen is actively preparing for its KOSDAQ listing in 2026, with Korea Investment & Securities serving as the lead underwriter.
